Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen, Biogen news

AMGN General Counsel Tom Workman said in a statement that the company is "confident that the making, using or selling of our Neupogen G-CSF does not infringe any valid, enforceable claim of the Biogen patent."

BioGenex Laboratories

BioTek Solutions Inc.

BioGenex (San

Read the full 428 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers